Akoustis Technologies Inc (AKTS)

$0.04 0.00 (-9.05%)
Market Cap 5.75M
Revenue (ttm) 27.38M
Net Income (ttm) -167.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -613.40%
Debt to Equity Ratio 0.00
Volume 118,703,398
Avg Vol 26,170,799
Day's Range N/A - N/A
Shares Out 154.59M
Stochastic %K 6%
Beta 1.91
Analysts Sell
Price Target $1.00

Company Profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 461 4023
Address:
17 Drydock Avenue, Suite 17-401, Boston, United States
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 12 at 7:27 PM
$AKTS are you kidding me or you people are haters? Because I married the daughter of a higher up in the company and was given practically free shares.? give my credit for gold digging
0 · Reply
vu_jade
vu_jade May. 12 at 6:25 PM
$AKTS inverse head and shoulders look
0 · Reply
WallStreetVice
WallStreetVice May. 12 at 5:08 PM
$AKTS looking solid for more
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 12 at 4:15 PM
$AKTS hit that follow button
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 12 at 4:14 PM
$AKTS this is what happens when you’re married to the daughter of a higher up in the company, he gives you a ton of free shares.
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 6 at 2:58 PM
$AKTS 🛑🛑everything is a scam collusion manipulation call out what you want. That is what’s going on in this country. Do anything to get ahead
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 6 at 2:57 PM
$AKTS this is what happens when you marry the daughter of a higher up in the company you get a ton of shares, practically for free. It’s like the liberal party with inside information and given free shares. It’s all good. They can do it. Why can’t the public?
0 · Reply
focafoca99
focafoca99 May. 4 at 10:22 AM
$AKTS posted an oversubscribed IPO in 2026.
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 30 at 3:59 PM
$RADX Asymmetrical upside right from CEO’s slide. Gotta be in it to win it. $CATX $LNTH $PSTV $AKTS
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 1:04 AM
$AKTS
0 · Reply
Latest News on AKTS
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M

2026-05-11T21:36:58.000Z - 1 day ago

Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

May 11, 2026, 4:01 PM EDT - 1 day ago

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Aktis Oncology to Present at the BofA Securities Health Care Conference

May 6, 2026, 8:00 AM EDT - 7 days ago

Aktis Oncology to Present at the BofA Securities Health Care Conference

Aktis Oncology Transcript: Study update

May 5, 2026, 8:00 AM EDT - 8 days ago

Aktis Oncology Transcript: Study update

Aktis Oncology initiates clinical trial of AKY-25191

2026-05-04T21:11:48.000Z - 8 days ago

Aktis Oncology initiates clinical trial of AKY-25191

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

May 4, 2026, 4:05 PM EDT - 8 days ago

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Aktis Oncology initiated with an Outperform at William Blair

2026-04-29T10:50:44.000Z - 14 days ago

Aktis Oncology initiated with an Outperform at William Blair

Aktis Oncology appoints Gormley as independent director of Board of Directors

2026-04-16T14:16:14.000Z - 26 days ago

Aktis Oncology appoints Gormley as independent director of Board of Directors

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

Apr 16, 2026, 8:00 AM EDT - 27 days ago

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright

2026-03-31T10:31:00.000Z - 6 weeks ago

Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright

Aktis Oncology announces FDA clearance of AKY-25191 trial

2026-03-30T20:17:16.000Z - 6 weeks ago

Aktis Oncology announces FDA clearance of AKY-25191 trial

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Mar 30, 2026, 4:01 PM EDT - 6 weeks ago

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Aktis Oncology Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:40 PM EDT - 2 months ago

Aktis Oncology Transcript: Leerink Global Healthcare Conference 2026

Aktis Oncology initiated with a Buy at H.C. Wainwright

2026-03-09T10:21:33.000Z - 2 months ago

Aktis Oncology initiated with a Buy at H.C. Wainwright

Aktis Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 2 months ago

Aktis Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Aktis Oncology to Present at Upcoming March Investor Conferences

Feb 24, 2026, 4:05 PM EST - 2 months ago

Aktis Oncology to Present at Upcoming March Investor Conferences

Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189

2026-02-24T13:12:13.000Z - 2 months ago

Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Feb 24, 2026, 8:00 AM EST - 2 months ago

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Aktis Oncology initiated with an Outperform at Leerink

2026-02-03T11:30:36.000Z - 3 months ago

Aktis Oncology initiated with an Outperform at Leerink

Aktis Oncology initiated with a Buy at BofA

2026-02-03T11:25:45.000Z - 3 months ago

Aktis Oncology initiated with a Buy at BofA

Aktis Oncology initiated with a Buy at TD Cowen

2026-02-03T10:40:19.000Z - 3 months ago

Aktis Oncology initiated with a Buy at TD Cowen

Aktis Oncology initiated with an Overweight at JPMorgan

2026-02-03T10:00:20.000Z - 3 months ago

Aktis Oncology initiated with an Overweight at JPMorgan

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 13, 2026, 6:30 AM EST - 4 months ago

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO

2026-01-12T16:15:19.000Z - 4 months ago

Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO

ANDG BUDA FJET MDLN

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

Jan 9, 2026, 12:58 PM EST - 4 months ago

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

LLY

Aktis Oncology prices upsized US IPO at $18 per share

Jan 8, 2026, 9:20 PM EST - 4 months ago

Aktis Oncology prices upsized US IPO at $18 per share

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Jan 8, 2026, 8:48 PM EST - 4 months ago

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Aktis Oncology files for US IPO as biotech listings rebound

Dec 19, 2025, 5:51 PM EST - 5 months ago

Aktis Oncology files for US IPO as biotech listings rebound

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO

Dec 19, 2025, 5:51 PM EST - 5 months ago

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO

Aktis Oncology IPO Registration Document (S-1)

Dec 19, 2025, 4:02 PM EST - 5 months ago

Aktis Oncology IPO Registration Document (S-1)

Akoustis to pursue sale through chapter 11 process

2024-12-16T10:30:55.000Z - 1 year ago

Akoustis to pursue sale through chapter 11 process

QRVO

DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 12 at 7:27 PM
$AKTS are you kidding me or you people are haters? Because I married the daughter of a higher up in the company and was given practically free shares.? give my credit for gold digging
0 · Reply
vu_jade
vu_jade May. 12 at 6:25 PM
$AKTS inverse head and shoulders look
0 · Reply
WallStreetVice
WallStreetVice May. 12 at 5:08 PM
$AKTS looking solid for more
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 12 at 4:15 PM
$AKTS hit that follow button
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 12 at 4:14 PM
$AKTS this is what happens when you’re married to the daughter of a higher up in the company, he gives you a ton of free shares.
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 6 at 2:58 PM
$AKTS 🛑🛑everything is a scam collusion manipulation call out what you want. That is what’s going on in this country. Do anything to get ahead
0 · Reply
DarkPoolMoneyMaker
DarkPoolMoneyMaker May. 6 at 2:57 PM
$AKTS this is what happens when you marry the daughter of a higher up in the company you get a ton of shares, practically for free. It’s like the liberal party with inside information and given free shares. It’s all good. They can do it. Why can’t the public?
0 · Reply
focafoca99
focafoca99 May. 4 at 10:22 AM
$AKTS posted an oversubscribed IPO in 2026.
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 30 at 3:59 PM
$RADX Asymmetrical upside right from CEO’s slide. Gotta be in it to win it. $CATX $LNTH $PSTV $AKTS
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 1:04 AM
$AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 2:00 PM
$RADX ((data in June)) Strong data (≈90%) ✅ your base case What it means: Clearly better than MRI Clinically meaningful differentiation Opens door to: Acquisition Fast-track Phase 3 Valuation logic: RAD101 = $400–600M asset Add small therapeutic optionality 👉 Market cap: $300–500M 👉 Stock price: $25 – $42 $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 1:57 PM
$RADX RADX is the only one where success is NOT priced in — and it's the closest to proving it. $AKTS $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 24 at 1:55 PM
$RADX Mispricing summary Company Expected Value Current Value Mispricing RADX ~$525M ~$60M ~9x undervalued AKTS ~$300M ~$1B ~3x overvalued CATX ~$140M ~$550M ~4x overvalued $AKTS $CATX
0 · Reply
STACKD0E
STACKD0E Apr. 23 at 4:21 PM
$CRBU $AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 22 at 2:31 PM
There’s a value arbitrage of about $800 million between $RADX and $AKTS if you back out the cash balance of AKTS. RADX pipe is actually just as good or better. And there lead asset RAD101 could deposit a huge amount of cash onto RADX’s balance sheet if a deal is struck.
0 · Reply
STACKD0E
STACKD0E Apr. 22 at 1:31 AM
$CRBU $AKTS 🙃✨️
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 21 at 2:36 PM
$AKTS is on fire and $RADX has just as good or better radiopharmaceuticals and much deeper pipeline and backed by a premier radiopharma company Lantheus $LNTH
0 · Reply
k3n888
k3n888 Apr. 21 at 12:37 AM
$AKTS take note this is an Eli Lilly backed pharma company...
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 12 at 12:26 PM
$RADX https://youtube.com/shorts/G9QrVARx8q4?si=XA2hXyaAraQJWpob $AKTS $TLX $CATX $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 12 at 1:58 AM
$AKTS $CATX $TLX $RADX
0 · Reply
RadioIsotope25
RadioIsotope25 Apr. 10 at 4:19 PM
$RADX Top 10 reasons why Lantheus should buy Radiopharm Theranostics. $LNTH $TLX $CATX $AKTS
0 · Reply
PHARMD09
PHARMD09 Apr. 8 at 3:48 PM
$AKTS
0 · Reply